ArticleJournal of nanobiotechnology2023
Targeted co-delivery of curcumin and erlotinib by MoS
Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Light as a master switch: a critical review of photonanozymes from design to applications.Advanced biotechnology · 2026Review
- Multi-Target Antitumor Effects of Natural Products and Approved Drug Repurposing in Non-Small Cell Lung Cancer: Advances in Mechanisms, Combination Regimens, Delivery System Optimization, and Clinical Challenges.International journal of molecular sciences · 2026Review
- Hericium erinaceus β-Glucan Improves Post-Prandial Glycemic Homeostasis in Association With Changes in Akkermansia muciniphila, Serum Metabolites, and Gut Hormones.Journal of food science · 2026Article
- Engineered MoSNanomaterials (Basel, Switzerland) · 2026Review
- Dual tumor microenvironment-responsive albumin nanoplatform integrates conditional PROTAC activation with starvation and ferroptosis for synergistic cancer therapy.Journal of nanobiotechnology · 2026Article
- Recent Advances in Antitumor Nanomedicine Based on Covalent Organic Frameworks.International journal of nanomedicine · 2026Review
- Traditional Chinese medicine in lung cancer treatment.Molecular cancer · 2025Review
- Anti-Tumor Strategies of Photothermal Therapy Combined with Other Therapies Using Nanoplatforms.Pharmaceutics · 2025Review
- NIR-activated catechol-functionalized nanodiamond nanofibers for accelerating on-demand MRSA and E. coli biofilm eradication.Journal of biological engineering · 2025Article
- How Traditional Chinese Medicine Can Play a Role In Nanomedicine? A Comprehensive Review of the Literature.International journal of nanomedicine · 2025Review
- Exploring the application of metal-based photothermal agents in photothermal therapy combined with immune checkpoint therapy.Frontiers in pharmacology · 2025Review
- Recent developments in two-dimensional molybdenum disulfide-based multimodal cancer theranostics.Journal of nanobiotechnology · 2024Review
- Biomimetic nanodrug blocks CD73 to inhibit adenosine and boosts antitumor immune response synergically with photothermal stimulation.Journal of nanobiotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCurcumin (Cur), a bioactive component of Chinese traditional medicine, has demonstrated inhibitory properties against cancer cell proliferation while synergistically enhancing the anticancer efficacy of erlotinib (Er). However, the individual limitations of both drugs, including poor aqueous solubility, lack of targeting ability, short half-life, etc., and their distinct pharmacokinetic profiles mitigate or eliminate their combined antitumor potential.
resultsIn this study, we developed a molybdenum disulfide (MoS
conclusionsThe as-synthesized MoS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.